This episode opens with a practical discussion of systemic therapy selection in advanced pancreatic cancer, weighing FOLFIRINOX, modified triplet regimens, and gemcitabine/nab-paclitaxel in real-world patients. Dr. Jonathan Mizrahi and Dr. Shubham Pant highlight how age, performance status, and time toxicity factor into first-line decisions, and how second-line therapy remains largely sequential and limited. Then they turn to molecular profiling, emphasizing early and reflex NGS testing despite low rates of actionable alterations. While targeted options remain rare, emerging KRAS and fusion-directed therapies signal cautious optimism that pancreatic cancer treatment may finally be entering a more precision-driven era.
Contributors:
Dr. Jonathan Mizrahi is a medical oncologist with Ochsner Health in New Orleans, Louisiana.
Dr. Shubham Pant is a professor with the Department of Gastrointestinal Medical Oncology and Investigational Cancer Therapeutics at the University of Texas MD Anderson Cancer Center in Houston, Texas.
